HBV Post-Transplant Prophylaxis — SCE Infectious Diseases MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Lifelong HBIG plus nucleos(t)ide analogue (or nucleos(t)ide analogue alone in some protocols) to prevent HBV recurrence in the graft
Post-liver transplant for HBV-related disease, HBV recurrence in the new graft is a major risk. Prophylaxis with HBIG (hepatitis B immunoglobulin) plus a nucleos(t)ide analogue (Entecavir or Tenofovir) is the standard approach, often lifelong. Some centres now use nucleos(t)ide analogue monotherapy after an initial period of HBIG. Without prophylaxis, HBV recurrence rates exceed 80%. The goal is to maintain undetectable HBV DNA and adequate anti-HBs levels.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/infections